Glaucoma Intensity Treatment Study – Intensive non-invasive glaucoma treatment vs conventional stepwise treatment – a prospective, randomized phase IV study of disease progression in glaucoma

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-510041-16-00

Acronym

GITS

Enrollment

240

Registered

2024-05-16

Start date

2013-04-22

Completion date

Unknown

Last updated

2024-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma, open-angle and PEX glaucoma

Brief summary

Rate of progression, the aim of the study is to compare and follow-up the patients on traditional clinical treatment with those receiving more intensive treatment, and measure the rate of progression as long as possible.

Detailed description

Quality of life, Compliance and adherence

Interventions

DRUGTIMOLOL

DRUGBRIMONIDINE

DRUGPILOCARPINE

DRUGBRINZOLAMIDE

DRUGLATANOPROST

DRUGCOMBINATIONS

DRUGTRAVOPROST

DRUGBETAXOLOL

DRUGBIMATOPROST

DRUGDORZOLAMIDE

DRUGTAFLUPROST

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Rate of progression, the aim of the study is to compare and follow-up the patients on traditional clinical treatment with those receiving more intensive treatment, and measure the rate of progression as long as possible.	—

Secondary

Measure	Time frame
Quality of life, Compliance and adherence	—

Countries

Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026